Tyler Stone Wealth Management Has $220,000 Stock Position in VanEck Biotech ETF (NASDAQ:BBH)

Tyler Stone Wealth Management lowered its position in shares of VanEck Biotech ETF (NASDAQ:BBH) by 5.0% during the fourth quarter, Holdings Channel reports. The fund owned 1,399 shares of the company’s stock after selling 73 shares during the quarter. Tyler Stone Wealth Management’s holdings in VanEck Biotech ETF were worth $220,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Tocqueville Asset Management L.P. purchased a new position in VanEck Biotech ETF during the 4th quarter worth approximately $860,000. Farther Finance Advisors LLC acquired a new stake in shares of VanEck Biotech ETF in the fourth quarter worth $32,000. HighTower Advisors LLC grew its holdings in shares of VanEck Biotech ETF by 12.0% during the fourth quarter. HighTower Advisors LLC now owns 9,903 shares of the company’s stock valued at $1,554,000 after buying an additional 1,058 shares in the last quarter. Independent Advisor Alliance acquired a new position in VanEck Biotech ETF during the fourth quarter valued at $250,000. Finally, Raymond James Financial Inc. purchased a new stake in VanEck Biotech ETF in the 4th quarter worth about $3,381,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Trading Down 1.1 %

Shares of NASDAQ BBH opened at $158.92 on Thursday. The firm has a market capitalization of $387.76 million, a PE ratio of 33.67 and a beta of 0.85. VanEck Biotech ETF has a one year low of $151.35 and a one year high of $183.64. The business has a 50-day moving average price of $162.99 and a two-hundred day moving average price of $166.79.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.